Genomi-k provides neonatal genomic diagnosis solutions to detect and identify hearing, metabolism, and heart diseases in newborns. Their biotech platform offers early detection capabilities for critical health conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Newborns are vulnerable to a range of congenital conditions, including metabolic disorders, hearing loss, and critical heart defects, which can have long-term health consequences if not detected early. Traditional screening methods may not be comprehensive or accessible, leading to delayed diagnosis and intervention.
Solution
Genomi-k provides comprehensive neonatal screening programs designed for the early detection and intervention of metabolic, auditory, and cardiac diseases. Their services, Támi-k®, Áudi-k®, and Cárdi-k®, offer integrated screening for metabolic disorders, hearing loss, and critical congenital heart defects, respectively. Genomi-k supports hospitals and healthcare providers with timely results, follow-up medical guidance, and specialized care pathways to ensure prompt attention for newborns identified with potential health issues. Their approach includes advanced technologies and genetic testing to improve the accuracy and reliability of screening, facilitating early diagnosis and treatment.
Target Audience
The primary target audience includes hospitals, healthcare providers, pediatricians, and neonatologists involved in newborn care and early disease detection.
Features
- Támi-k®: Comprehensive metabolic screening program with an expanded panel of detectable diseases and DNA-based testing for precise results.
- Áudi-k®: Integrated hearing screening program utilizing advanced technologies to determine potential hearing loss, including genetic testing for confirmed cases of hypoacusis.
- Cárdi-k®: Cardiac screening program for the detection of seven critical congenital heart defects using automated pulse oximetry in the hand and foot.
- Follow-up support: Medical guidance and specialist consultations for hospitals and healthcare providers in case of detected conditions.
- Rapid results: Delivery of screening results to hospitals within 24 hours (Áudi-k® and Cárdi-k®) or 6 days (Támi-k®).
- Adherence to standards: Medical protocols based on guidelines from the American Academy of Pediatrics (AAP) and the American Heart Association (AHA).